<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70110">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02193074</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 396443-CS3B</org_study_id>
    <secondary_id>2013-004422-29</secondary_id>
    <nct_id>NCT02193074</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy</brief_title>
  <acronym>ENDEAR</acronym>
  <official_title>A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Infantile-onset Spinal Muscular Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to examine the clinical efficacy of nusinersen (ISIS
      396443) administered intrathecally (IT) to participants with infantile-onset SMA. The
      secondary objective of the study is to examine the safety and tolerability of nusinersen
      administered intrathecally to participants with infantile-onset SMA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was conducted and the protocol was registered by Ionis Pharmaceuticals, Inc..

      In August 2016, sponsorship of the trial was transferred to Biogen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)</measure>
    <time_frame>Up to Day 402</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to death or respiratory intervention</measure>
    <time_frame>Up to Day 402</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who attained Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND)</measure>
    <time_frame>Up to Day 402</time_frame>
    <description>CHOP-INTEND tests includes 16 items structured to move from easiest to hardest with the grading including gravity eliminated (lower scores) to antigravity movements (higher scores). All item scores range from 0-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>Up to Day 402</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants not requiring permanent ventilation</measure>
    <time_frame>Up to Day 402</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who attained Compound Muscular Action Potential (CMAP)</measure>
    <time_frame>Up to Day 402</time_frame>
    <description>CMAP is an electrophysiological technique that can be used to determine the approximate number of motor neurons in a muscle or group of muscles. Participants with peroneal CMAP amplitude increasing to or maintained at â‰¥ 1 mV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death or respiratory intervention in the subgroups of participants below the study median disease duration</measure>
    <time_frame>Up to Day 402</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death or respiratory intervention in the subgroups of participants above the study median disease duration</measure>
    <time_frame>Up to Day 402</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing Adverse events (AEs)</measure>
    <time_frame>Up to Day 402</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant vital sign abnormalities</measure>
    <time_frame>Up to Day 402</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant weight abnormalities</measure>
    <time_frame>Up to Day 402</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant neurological examination abnormalities</measure>
    <time_frame>Up to Day 402</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant physical examination abnormalities</measure>
    <time_frame>Up to Day 402</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant laboratory assessment abnormalities</measure>
    <time_frame>Up to Day 402</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities</measure>
    <time_frame>Up to Day 402</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in concomitant medications</measure>
    <time_frame>Up to Day 402</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Spinal Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>nusinersen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham procedure</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nusinersen</intervention_name>
    <description>Administered by intrathecal (IT) injection as specified in the treatment arm.</description>
    <arm_group_label>nusinersen</arm_group_label>
    <other_name>ISIS 396443</other_name>
    <other_name>BIIB058</other_name>
    <other_name>Spinraza</other_name>
    <other_name>IONIS-SMN Rx</other_name>
    <other_name>ISIS SMNRx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham procedure</intervention_name>
    <description>Small needle prick on the lower back at the location where the IT injection is normally made</description>
    <arm_group_label>Sham procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Be born (gestational age) between 37 and 42 weeks

          -  Be medically diagnosed with spinal muscular atrophy (SMA)

          -  Have Survival Motor Neuron2 (SMN2) Copy number = 2

          -  Body weight equal to or greater than 3rd percentile for age using appropriate
             country-specific guidelines

          -  Be able to follow all study procedures

          -  Reside within approximately 9 hours ground-travel distance from a participating study
             center, for the duration of the study

        Key Exclusion Criteria:

          -  Hypoxemia Oxygen (O2) saturation awake less than 96% or O2 saturation asleep less
             than 96%, without ventilation support) during screening evaluation

          -  Clinically significant abnormalities in hematology or clinical chemistry parameters
             or Electrocardiogram (ECG), as assessed by the Site Investigator, at the Screening
             visit that would render the participant unsuitable for participation in the study

          -  Participant's parent or legal guardian is not willing to meet standard of care
             guidelines (including vaccinations and respiratory syncytial virus prophylaxis if
             available), nor provide nutritional and respiratory support throughout the study

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>210 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital of Chicago Box 51</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Children's Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doernbecher Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia - Neurology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center/Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center (University of Utah)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital, Children's Neuroscience Centre</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Universitaire des Enfants Reine FABIOLA (HUDERF)</name>
      <address>
        <city>Brussels</city>
        <zip>15 - 1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital/UBC</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 0A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Myologie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtatsklinikum Freiburg, Zentrum fur Kinder-und Jugendmedizin , Abteilung Neuropadiatrie und Muskelerkrankungen</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini, Centro Traslazionale di Miologia e Patologie Neurodegenerative</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Neurology Unit, Catholic University</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine</name>
      <address>
        <city>Nishinomya-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University</name>
      <address>
        <city>Tokyo</city>
        <state>Tokyo Metropolitan Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Valle Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz, Pediatric Neurology Department</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Gothenburg, The Queen Silvia Children's Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe Children's Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Institute of Child Health/Great Ormond Street</name>
      <address>
        <city>London</city>
        <zip>WC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MRC Centre for Neuromuscular Diseases at Newcastle, Institute of Genetic Medicine Newcastle University</name>
      <address>
        <city>Newcastle</city>
        <zip>NE1 3BZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
    <country>Taiwan</country>
  </removed_countries>
  <link>
    <url>http://www.curesma.org</url>
    <description>Cure SMA</description>
  </link>
  <link>
    <url>http://mda.org/disease/spinal-muscular-atrophy</url>
    <description>Muscular Dystrophy Association</description>
  </link>
  <link>
    <url>https://www.rarediseases.org</url>
    <description>National Organization for Rare Diseases</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>July 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinal Muscular Atrophy</keyword>
  <keyword>SMA</keyword>
  <keyword>SMN</keyword>
  <keyword>SMNRx</keyword>
  <keyword>ISIS-SMNRx</keyword>
  <keyword>ISIS-SMN Rx</keyword>
  <keyword>ISIS 396443</keyword>
  <keyword>IONIS-SMNRx</keyword>
  <keyword>IONIS-SMN Rx</keyword>
  <keyword>Spinraza</keyword>
  <keyword>ENDEAR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
